UBE3C promotes pancreatic ductal adenocarcinoma progression by catalysing p53 ubiquitination
Molecular Biology Reports · 2025
DOI: 10.1007/s11033-025-10751-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Yang Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: the talent introduction project of Zhongnan Hospital of Wuhan University, the Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies worldwide. Ubiquitination is a biological process that regulates the degradation of proteins. Previous studies have indicated that ubiquitin ligase E3C (UBE3C) has procarcinogenic properties in various tumours. Nevertheless, the detailed role of UBE3C in PDAC is still unknown. METHODS AND RESULTS: Bioinformatics analyses of UBE3C were performed, and we found that UBE3C expression was increased in PDAC cells and indicates a poorer clinical prognosis. Moreover, a significant positive correlation existed between UBE3C expression and the number of CD4+ T cells in the tumour microenvironment (TME) of PDAC. CCK-8, colony formation, EdU and flow cytometry assays indicated that UBE3C knockdown promoted apoptosis and inhibited PDAC cell growth, whereas UBE3C overexpression had the opposite effects. Additionally, UBE3C catalysed p53 ubiquitination and promoted pancreatic carcinogenesis by facilitating p53 degradation. This effect was also confirmed in rescue experiments performed with pifithrin-α (PTF-α, an inhibitor of p53). CONCLUSIONS: Our results clarify the importance of UBE3C in PDAC and indicate that the UBE3C-p53 axis may be a novel therapeutic target for PDAC. CLINICAL TRIAL NUMBER: Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China.
- Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China.
- Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China. paulqqqqq@hotmail.com.
- Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China. yangzhiyong@whu.edu.cn.
Förderung
- the talent introduction project of Zhongnan Hospital of Wuhan University
- the Natural Science Foundation of Hubei Province
Zitieren
APA
Shi, Y., Wang, J., Cheng, Q., Wu, S., Qin, X., & Yang, Z. (2025). UBE3C promotes pancreatic ductal adenocarcinoma progression by catalysing p53 ubiquitination. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10751-5
Vancouver
Shi Y, Wang J, Cheng Q, Wu S, Qin X, Yang Z. UBE3C promotes pancreatic ductal adenocarcinoma progression by catalysing p53 ubiquitination. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10751-5
BibTeX
@article{Shi2025,
author = {Shi, Yang and Wang, Jiaxi and Cheng, Qian and Wu, Shuaihui and Qin, Xian and Yang, Zhiyong},
title = {UBE3C promotes pancreatic ductal adenocarcinoma progression by catalysing p53 ubiquitination},
journal = {Molecular Biology Reports},
year = {2025},
doi = {10.1007/s11033-025-10751-5}
}
EUVIMED